Compare Gap Inc (GAP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gap Inc vs Recursion Pharmaceuticals Inc — how do they compare? Gap Inc trades at $23.24 (market cap $8.21B), while Recursion Pharmaceuticals Inc trades at $4.27 (market cap $2.14B). The key difference: Gap Inc is far larger — about 3.8× Recursion Pharmaceuticals Inc's market cap, and Gap Inc pays a 3% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| GAP | RXRX | |
|---|---|---|
Market Cap | $8.21B | $2.14B |
Volume | 5,192,917 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $6.79 |
52-Week Low | $18.35 | $2.84 |
Typical Hold Time | 37 Days | 22 Days |
Enterprise Value | $11.44B | $1.66B |
Dividend Yield | 3% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $23.15, down 1.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The company shows strong profitability with a net income margin of 8.14% and ROE of 33.78%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include a 'fashiontainment' partnership with boy band JYT and a new board appointment, signaling strategic brand revitalization efforts.
The outlook for Gap is cautiously optimistic, with valuation metrics like a P/E of 7.04 and P/S of 0.58 suggesting potential upside. Key risks include uneven brand performance, with Old Navy sales declining, and macroeconomic pressures on consumer spending. Earnings growth and successful brand initiatives are critical catalysts for further stock appreciation.
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
